METABOLISM CLINICAL AND EXPERIMENTAL 61 (2012) 1696 1702. Available online at www.sciencedirect.com. Metabolism. www.metabolismjournal.



Similar documents
Diabetes mellitus. Lecture Outline

TYPE 2 DIABETES MELLITUS: NEW HOPE FOR PREVENTION. Robert Dobbins, M.D. Ph.D.

INSULIN AND INCRETIN THERAPIES: WHAT COMBINATIONS ARE RIGHT FOR YOUR PATIENT?

Introduction. Pathogenesis of type 2 diabetes

Cardiovascular Disease Risk Factors Part XII Insulin Resistance By James L. Holly, MD Your Life Your Health The Examiner September 15, 2005

Investigation of the effect of isomaltulose (PalatinoseTM) on metabolic parameters in subjects with Type 2 Diabetes.

Protein Intake in Potentially Insulin Resistant Adults: Impact on Glycemic and Lipoprotein Profiles - NPB #01-075

Sponsor. Novartis Generic Drug Name. Vildagliptin. Therapeutic Area of Trial. Type 2 diabetes. Approved Indication. Investigational.

HEALTH CLAIMS ON PECTINS APPROVED BY EFSA

Plasma glucose and insulin responses to mixed meals: Impaired fasting glucose re-visited

Nutrition. Type 2 Diabetes: A Growing Challenge in the Healthcare Setting NAME OF STUDENT

Effects of macronutrients on insulin resistance and insulin requirements

Dr. René Koopman Dept of Human Movement Sciences Maastricht University, the Netherlands

Is Chocolate Milk the answer?

Abdulaziz Al-Subaie. Anfal Al-Shalwi

嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯

Reversing type 2 diabetes: pancreas composition and function during return to normal glucose tolerance

Diabetes Mellitus. Melissa Meredith M.D. Diabetes Mellitus

Overview of Diabetes Management. By Cindy Daversa, M.S.,R.D.,C.D.E. UCI Health

The South Asian Indian Women s s Weight Loss Study. Latha Palaniappan, MD, MS BIRCWH Scholar October 20, 2005

Homeostatic Model Assessment (HOMA)

Medical Nutrition Therapy for Diabetes

Statins and Risk for Diabetes Mellitus. Background

PowerPoint Lecture Outlines prepared by Dr. Lana Zinger, QCC CUNY. 12a. FOCUS ON Your Risk for Diabetes. Copyright 2011 Pearson Education, Inc.

Diabetes and Obesity. The diabesity epidemic

Subcutaneous Infusion of GLP-1 for 7 Days Improves Glycemic Control Over a Broad Dose Range in Patients with Type 2 Diabetes

CME Test for AMDA Clinical Practice Guideline. Diabetes Mellitus

EFFIMET 1000 XR Metformin Hydrochloride extended release tablet

How you can achieve normal blood sugars with diet and insulin. Dr Katharine Morrison IDDT October 2007

What is Type 2 Diabetes?

A STUDY OF MAGNESIUM SUPPLEMENTATION ON GLYCEMIC CONTROL IN PATIENTS OF TYPE-2 DIABETES MELLITUS

Is Insulin Effecting Your Weight Loss and Your Health?

How To Determine The Prevalence Of Microalbuminuria

TYPE 2 DIABETES IN CHILDREN DIAGNOSIS AND THERAPY. Ines Guttmann- Bauman MD Clinical Associate Professor, Division of Pediatric Endocrinology, OHSU

Grow Taller 4 Idiots 2

Diabetes mellitus is a chronic condition that occurs as a result of problems with the production and/or action of insulin in the body.

DRUGS FOR GLUCOSE MANAGEMENT AND DIABETES

Protein. Protein. Why is protein important?

tips Insulin Pump Users 1 Early detection of insulin deprivation in continuous subcutaneous 2 Population Study of Pediatric Ketoacidosis in Sweden:

Diabetes Fundamentals

Jill Malcolm, Karen Moir

Appendix: Description of the DIETRON model

Insulin is a hormone produced by the pancreas to control blood sugar. Diabetes can be caused by too little insulin, resistance to insulin, or both.

DR. Trinh Thi Kim Hue

Amino Acid Composition of an Organic Brown Rice Protein Concentrate and Isolate Compared to Soy and Whey Concentrates and Isolates

Pipe Cleaner Proteins. Essential question: How does the structure of proteins relate to their function in the cell?

Effect of Added Fat on Plasma Glucose and Insulin Response to Ingested Potato Given in Various Combinations as T wo Meals in Type 2 Diabetic Patients

GLUCOSE HOMEOSTASIS-II: An Overview

Guidance for Industry

Guidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes

Dietary Composition for Weight Loss and Weight Loss Maintenance

Treating Patients with PRE-DIABETES David Doriguzzi, PA-C First Valley Medical Group. Learning Objectives. Background. CAPA 2015 Annual Conference

DIABETES MELLITUS. By Tracey Steenkamp Biokineticist at the Institute for Sport Research, University of Pretoria

Diabetes, hypertension and a lot more `in the elderly` JORIS SCHAKEL INTERNIST- CLINICAL GERIATRICIAN JGSCHAKEL@SEHOS.CW

Protein Sources and its Benefits

Reactive Hypoglycemia- is it a real phenomena among endurance athletes? by Dr. Trent Stellingwerff, PhD

Monitoring and Carbohydrate Counting: The Cornerstones of Diabetes Control. Linda Macdonald, M.D. November 19, 2008

Causes, incidence, and risk factors

Published Quarterly Mangalore, South India ISSN Volume 4, Issue 1; January-March 2005

Should We Count Fat and Protein in Bolus Insulin Dose Calculation: Does Carbohydrate Counting Work? Howard A. Wolpert, MD

ETIOLOGIC CLASSIFICATION. Type I diabetes Type II diabetes

Nutrient Reference Values for Australia and New Zealand

Sedentarity and Exercise in the Canadian Population. Angelo Tremblay Division of kinesiology

Sweet-taste receptors, glucose absorption and insulin release: Are LCS nutritionally active?

The basal plus strategy. Denis Raccah, MD, PhD Professor of Medicine University Hospital Sainte Marguerite Marseille FRANCE

EUROPEAN COMMISSION HEALTH & CONSUMER PROTECTION DIRECTORATE-GENERAL

Timing van voeding voeding voor, tijdens en na inspanning. Link physical activity nutrition. Outline. The human engine

Development of a Glycemic Index Database for Dietary Assessment. Sally F. Schakel, Rebecca Schauer, John H. Himes, Lisa Harnack, Nancy Van Heel

Objectives. What Is Diabetes? 1/26/2015. Carbs & Meds & Meters, Oh My!: Diabetes in Pregnancy

Insulin Receptor Substrate 1 (IRS1) Gene Variation Modifies Insulin Resistance Response to Weight-loss Diets in A Two-year Randomized Trial

My Doctor Says I Need to Take Diabetes Pills and Insulin... What Do I Do Now? BD Getting Started. Combination Therapy

ALPHA (TNFa) IN OBESITY

Summary and conclusions. Chapter 8. Summary and conclusions

X-Plain Hypoglycemia Reference Summary

Improving cardiometabolic health in Major Mental Illness

DIABETES MEDICATION-ORAL AGENTS AND OTHER HYPOGLYCEMIC AGENTS

Insulin s Effects on Testosterone, Growth Hormone and IGF I Following Resistance Training

Updates for your practice March, Vol 2, Issue 14 TLALELETSO. Managing Complicated Diabetes

Chapter 25: Metabolism and Nutrition

Concluding lesson. Student manual. What kind of protein are you? (Basic)

Glycemic Control of Type 2 Diabetes Mellitus

Nonalcoholic Fatty Liver Disease. Dietary and Lifestyle Guidelines

Textbook: Chapter 12 pages , Chapter 13 pages

Calculating and Graphing Glucose, Insulin, and GFR HASPI Medical Biology Activity 19c

Diabetes and Weight-Loss Surgery

Role of Body Weight Reduction in Obesity-Associated Co-Morbidities

CHAPTER V DISCUSSION. normal life provided they keep their diabetes under control. Life style modifications

Long term Weight Management in Obese Diabetic Patients Osama Hamdy, MD, PhD, FACE

Practical Applications of Insulin Pump Therapy in Type 2 Diabetes

Patients with COPD were recruited according to the inclusion criteria; aged 40-75, current or

WHAT IS DIABETES MELLITUS? CAUSES AND CONSEQUENCES. Living your life as normal as possible

INJEX Self Study Program Part 1

INFORMATION BROCHURE GLUCAM study The Blood Glucose and Insulin Responses After Drinking of Camel Milk December 2011 January 2012

NCT sanofi-aventis HOE901_3507. insulin glargine

Copyright Mark Brandt, Ph.D. 35

Amino Acids, Peptides, Proteins

Take a moment Confer with your neighbour And try to solve the following word picture puzzle slides.

Detailed Course Descriptions for the Human Nutrition Program

Basal Insulin Analogues Where are We Now?

Determination of the anabolic response to exercise. Ingestion of Casein and Whey Proteins Result in Muscle Anabolism after Resistance Exercise

Transcription:

Available online at www.sciencedirect.com Metabolism www.metabolismjournal.com Combining protein and carbohydrate increases postprandial insulin levels but does not improve glucose response in patients with type 2 diabetes Meidjie Ang a, Andreas S. Müller b, Florian Wagenlehner c, Adrian Pilatz c, Thomas Linn a, a Medizinische Klinik und Poliklinik III, Justus-Liebig-Universität, 35392 Giessen, Germany b Institut für Agrar- und Ernährungswissenschaften, Martin-Luther-Universität, Halle-Wittenberg, Germany c Klinik für Urologie, Kinderurologie und Andrologie, Universitätsklinikum Giessen und Marburg GmbH, Giessen, Germany ARTICLE INFO ABSTRACT Article history: Received 11 October 2011 Accepted 9 May 2012 Keywords: Isomaltulose Protein Insulin action Postprandial glucose metabolism Type 2 diabetes Objective. A combined load of carbohydrate and protein stimulates insulin secretion. However, results on postprandial glucose responses in type 2 diabetic (T2D) subjects have been inconclusive. Therefore, we investigated the effects of co-ingestion of carbohydrate and protein on glucose and insulin responses in these subjects. Methods. After an overnight fast, 30 subjects consumed a drink containing 50 g of slowlydigested isomaltulose (ISO), combined either with a mixture of 21 g whey/soy (ISO+WS) or with 21 g casein (ISO+C) in a randomized order on separate days. In another experiment, the subjects consumed a control drink containing only 50 g ISO. Results. No significant differences in glucose responses were observed after ingestion of the drinks. Compared to ingestion of ISO alone, insulin response was ~190% 270% higher (P<.001), whereas insulin action was lower (P<.01) after ingestion of ISO+WS and ISO+C. Plasma insulin levels increased more significantly (P<.001) after ingestion of ISO+WS compared to ISO+C and were positively correlated with total amino acid levels (P<.001). Insulin action, however, showed a greater decrease following ingestion of ISO+WS than ISO+C (P<.01). Conclusions. Combining carbohydrate with protein can elevate postprandial insulin levels, but decreases insulin action, and therefore does not improve glucose response in T2D subjects. Our results further suggest that different types of proteins (i.e., fastabsorbing whey/soy vs. slow-absorbing casein) differently modulate insulin response and insulin action. A fast-absorbing protein mixture reduces insulin action to a greater extent than a slow-absorbing protein, and therefore may not be recommended for glycemic control in T2D patients. 2012 Elsevier Inc. All rights reserved. Abbreviations: BCAA, branched-chain amino acid; BMI, body mass index; EAA, essential amino acid; HbA 1c, glycated hemoglobin; HOMA-IR, homeostasis model assessment of insulin resistance; iauc, incremental area under the curve; ISO, isomaltulose; ISO+C, isomaltulose combined with casein; ISO+WS, isomaltulose combined with whey and soy (ratio 1:1); SEM, standard error of the mean; S I, insulin sensitivity index; TAA, total amino acid; T2D, type 2 diabetic; r s, Spearman's correlation coefficient. Corresponding author. Tel.: +49 641 985 42841; fax: +49 641 985 42849. E-mail address: thomas.linn@innere.med.uni-giessen.de (T. Linn). 0026-0495/$ see front matter 2012 Elsevier Inc. All rights reserved. http://dx.doi.org/10.1016/j.metabol.2012.05.008

1697 1. Introduction Table 1 Patients characteristics (n=30). Sex (female/male) 12/18 Age (years) 62.9±1.3 Body weight (kg) 85.6±3.1 Height (m) 1.7±0.02 BMI (kg/m 2 ) 29.0±0.7 HbA 1c (%) 6.6±0.1 HOMA-IR 4.0±0.6 Diabetes duration (years) 5.2±2.6 Metformin (female/male) 8/11 BMI, body mass index; HbA 1c, glycated hemoglobin; HOMA-IR, homeostasis model assessment of insulin resistance. Data are mean±sem. Table 2 Amino acid composition (g/100 g protein). Whey/Soy Casein Alanine 3.8 2.8 Arginine 4.7 3.4 Aspartic acid 12.2 6.6 Cyst(e)ine 2.1 0.4 Glutamic acid 18.0 20.2 Glycine 3.2 1.7 Histidine 2.4 2.9 Isoleucine 5.9 5.2 Leucine 8.7 9.1 Lysine 7.2 7.5 Methionine 1.5 2.7 Phenylalanine 4.3 4.9 Proline 4.8 9.5 Serine 5.2 5.7 Threonine 5.2 4.2 Tryptophan 2.3 1.3 Tyrosine 3.4 5.2 Valine 5.2 6.7 Whey/Soy (ratio 1:1). Postprandial hyperglycemia plays an important role in the development of cardiovascular complications in patients with type 2 diabetes [1,2]. To reduce the incidence and progression of these complications, an optimal glycemic control strategy should be considered in the treatment [3,4]. Several reviews reported that nutrition and lifestyle interventions can be effective in delaying the onset of the disease [5 7]. Meta-analyses of randomized controlled trials reported that a low glycemic index diet has a clinically relevant effect on glycemic control [8,9]. The glycemic index, originally described by Jenkins et al. [10], is a ranking system that measures the extent to which carbohydrates affect postprandial blood glucose levels. Carbohydrates with a low glycemic index are usually slowlyabsorbed, producing delayed gradual rises in blood glucose and insulin levels. For example, isomaltulose (ISO) is an isomer of sucrose which is digested slower than other sugars such as sucrose or maltose [11]. Studies on blood glucose, fructose, and insulin levels after oral administration of ISO have generally confirmed its suitability for diabetic subjects [11 13]. The dietary macronutrients carbohydrates, proteins, and fats are usually ingested in a complex food matrix rather than in their pure form. As a consequence, interactions between the macronutrients may influence glycemic response. Understanding nutrient interdependencies is therefore important. For instance, food proteins alone already stimulate insulin release, whereas a notably additive effect on insulin release is triggered by the combined uptake of proteins with carbohydrates [14 18]. However, controversial results have been reported in regard to the effects of insulin stimulation on glucose homeostasis in type 2 diabetic (T2D) subjects. Some studies have shown a reduction of postprandial glucose response when proteins and carbohydrates were taken up in combination compared to the uptake of carbohydrates alone [14,17,18]. Other studies did not confirm this effect [15,16]. In this context, various proteins were studied and it remains to be clarified whether they have comparable and consistent effects on postprandial glucose. In animal studies, it was reported that a protein mixture of whey and soy has potent postprandial glucose-attenuating and insulin-stimulating effects. These were also observed when the proteins were simultaneously ingested with a slowrelease carbohydrate [19]. In the present study, an isonitrogenous mixture of whey and soy proteins, as well as casein, was used as protein sources. We investigated whether a combined load of protein and slowly digested ISO could reduce postprandial glucose response in T2D subjects. 2. Subjects and methods 2.1. Subjects Thirty T2D subjects with good glycemic control (HbA 1c <7%, Table 1) were recruited from the University Hospital of Giessen, Germany and were treated with dietary advice and/or metformin. No other anti-diabetic medication was allowed. Metformin administration was stopped three days prior to the tests. Exclusion criteria include unstable or untreated proliferative retinopathy, clinically significant nephropathy, neuropathy, hepatic diseases, heart failure, uncontrolled hypertension, systemic treatment with corticosteroids, and insulin treatment. Prior to the study, all subjects underwent a thorough physical examination, as well as laboratory testing (blood cell count, liver and kidney chemistry, urine analysis, pregnancy test in premenopausal women, electrocardiography). The purpose was to exclude pregnancy and persons with medical conditions (e.g., cerebrovascular or coronary artery disease), which would complicate the evaluation of the tests. The study was conducted according to the guidelines set out in the Declaration of Helsinki and all procedures involving human subjects were approved by the Ethics Committee of the Justus Liebig University (Giessen, Germany). Written informed consent was obtained from all subjects. 2.2. Study design Each subject participated in 3 different experiments with a minimum 3-day washout period between two experiments. Subjects were randomized to ingest either a drink containing 50 g ISO with 21 g whey/soy (ratio 1:1) (ISO+WS) or a drink

1698 METABOLISM CLINICAL AND EXPERIMENTAL 61 (2012) 1696 1702 containing 50 g ISO with 21 g casein (ISO+C). In another experiment, the subjects were given a control drink containing only 50 g ISO. All experimental drinks were prepared from powder (Nutricia, Wageningen, Netherlands), dissolved in water. The amino acid composition of whey/soy and casein is listed in Table 2. To exclude any possible interactions, no other nutrients were added to the drinks. 2.3. Study protocol Subjects were admitted to the Clinical Research Unit at 08:00 h after an overnight fast. Basal blood samples were drawn from the antecubital vein before the start of the study. Thereafter, the subjects consumed the drinks containing only ISO, ISO+WS or ISO+C within 5 min. Blood samples were taken at 15, 30, 45, 60, 75, and 90 min after ingestion of the drinks, subsequently at every 30 min until blood glucose levels returned to baseline. Blood samples were collected into lithium heparin-coated tubes for the measurement of glucose, insulin, and amino acids. They were immediately centrifuged at 2000 g for 10 min. Aliquots of plasma were analyzed for glucose and insulin concentrations. The remaining samples were frozen and stored at 20 C until the analysis of the amino acids. 2.4. Analysis Plasma glucose concentrations were measured by the glucose hexokinase method (Bayer ADVIA, Germany). Plasma insulin concentrations were determined using a sandwich immunoassay based on a direct luminescence technique (Bayer ADVIA Centaur, Germany). Coefficients of variation for intra- and interassay precisions of glucose and insulin measurements were<6%. Amino acids were determined by high performance liquid chromatography using the fluorometric detection after precolumn derivatization with ortho-phthaldialdehyde. 2.5. Calculations Homeostasis model assessment of insulin resistance (HOMA- IR) was calculated with HOMA=(G 0 I 0 )/405 where G 0 is the fasting plasma glucose (mg/dl) and I 0 is the fasting plasma insulin (μu/ml) [20]. Plasma glucose and insulin curves were fitted using an equation described by Trujillo-Arriaga and Roman-Ramos [21]. Glucose, insulin, and amino acid responses were calculated as incremental areas under the curves (iaucs) above the baseline level. Incremental AUCs were calculated using GraphPad Prism 5. Insulin action was assessed in the postprandial state using the oral glucose minimal model [22]. The model provides an insulin sensitivity index (S I, dl/kg min per pmol/l), which is based on the total integrated AUCs of glucose and insulin concentrations assuming that the systemic glucose disposal equals the glucose entering the peripheral circulation. S IðoralÞ = f D oral AUC½ΔGðÞ= t Gt ðþš AUC ΔGðÞ t ½ Š GE AUC½ΔGðÞ= t Gt ðþš AUC½ΔIðÞ tš where ΔG (mg/dl) and ΔI (pmol/l) are glucose and insulin concentrations above basal, ΔG(t)=G(t) G b,δi=i(t) I b. AUC is ð1þ calculated from 0 to 240 min, GE is glucose effectiveness, D oral is the dose of ingested carbohydrate per unit of body weight (mg/kg) and f is the fraction of ingested glucose that appears in the systemic circulation. GE was fixed at 0.024 dl/kg min and f was set at 0.8 [22]. When glucose concentration falls below baseline, the equation becomes S IðoralÞ = AUC½ΔGðÞ= t Gt ðþš t 0 AUC 0 f D ½ ΔGðÞ= t Gt ðþš t 0 oral AUC½ΔGðÞ tš t 0 AUC ΔG t 0 ðþ GE AUC½ΔGðÞ= t Gt ðþš ½ Š t 0 AUC½ΔIðÞ tš ð2þ t 0 is the time when glucose concentration crosses the baseline level. S I measures the overall effect of insulin to stimulate glucose disposal and inhibit glucose production [23]. 2.6. Statistical analysis All data are expressed as mean ±SEM. The Kolmogorov Smirnov test was used to evaluate the normality of the data. Comparisons between the drinks at different time points were analyzed by using two-way repeated measures ANOVA with drink and time as within-subject factors. When the data violated the assumption of sphericity for homogeneity of variances, Greenhouse Geisser correction was used. For nontime-dependent variables, one-way repeated measures ANOVA or Friedman test was used to analyze data set with or without normality of distribution, respectively. If the test revealed significant changes and the normality assumption was not violated, Bonferroni post hoc test was further applied for multiple comparisons between the drinks. For data set without normality of distribution, Wilcoxon signed-rank test with Bonferroni correction was chosen as post hoc test for multiple comparisons between the drinks. Spearman's correlation coefficient (r s ) was used to assess the relationship between insulin and amino acids. Analysis was performed by using SPSS 16. Differences between means with an error probability of P<.05 were considered statistically significant. In case of Bonferroni corrections, the significance level was set at P<.05/number of comparisons. 3. Results 3.1. Plasma glucose and insulin concentrations Fasting plasma glucose levels did not differ between the study days on which only ISO, ISO+ WS, or ISO+C was ingested (P=.648, Table 3). After ingestion of ISO alone, ISO+WS, and ISO+C, plasma glucose concentrations increased significantly above the baseline level (P<.001) and reached peak values at~75 min. Glucose responses did not differ following ingestion of the different drinks (P=.239, Fig. 1A). Accordingly, fasting plasma insulin levels did not differ between the days of ingestion of ISO alone, ISO+WS, and ISO+ C(P=.525, Table 3). Plasma insulin concentrations increased from baseline (P<.001) to peak levels after~90 min consumption of the different drinks. Insulin responses were~270% and~190% higher after ingestion of ISO+WS and ISO+C than after ingestion of ISO alone (P<.001). Following intake of ISO+

1699 Table 3 Plasma glucose and insulin after ingestion of drinks containing only ISO, ISO+WS, and ISO+C in 30 type 2 diabetic patients. ISO ISO+WS ISO+ C Overall P value a P value ISO vs. ISO+WS ISO vs. ISO+C ISO+WS vs. ISO+C Plasma glucose Baseline (mmol/l) 7.1±0.2 7.2±0.3 7.2±0.3.648 NA NA NA Peak (mmol/l) 11.2±0.3 11.1±0.4 10.9±0.4.656 NA NA NA Peak time (min) 77.5±4.0 78.5±4.4 76.0±4.0.639 NA NA NA Plasma insulin Baseline (pmol/l) 77.1±2.9 88.6±11.2 76.5±11.8.525 NA NA NA Peak (pmol/l) 212.4±10.2 571.9±47.0 445.4±38.6 <.001 <.001 <.001 <.001 Peak time (min) 94.0±4.1 94.0±7.3 95.5±10.0.515 NA NA NA S I (10 5 dl/kg min per pmol/l) 16.3±2.0 5.9 ±0.8 10.4±1.8 <.001 <.001.005.003 ISO, isomaltulose; ISO+WS, isomaltulose combined with whey/soy (ratio 1:1); ISO+C, isomaltulose combined with casein; S I, insulin sensitivity index; NA, not applicable (due to non-significant overall P value). Data are mean±sem. a A P value<.0167 was considered significant (Bonferroni adjustment for 3 comparisons). iauc (mmol/l.4h) WS, insulin response was~30% higher compared to that observed following intake of ISO+C (P=.002, Fig. 1B). 3.2. Insulin action Net S I was lower after ingestion of ISO+ WS and ISO+C than after ingestion of ISO alone (P<.001 and P=.005, respectively). Moreover, S I was lower following intake of ISO+WS compared to that following intake of ISO+C (P=.003, Table 3). 3.3. Plasma amino acid concentrations A B Time (min) Time (min) Fig. 1 Plasma glucose and insulin after ingestion of drinks containing only ISO (grey), ISO+WS (black), and ISO+C (white) in 30 type 2 diabetic patients. (A) No significant drink effect (P=.704) or drink time interaction (P=.411) was found for glucose concentrations. Glucose iaucs were not significantly different between the drinks (P=.239). (B) A significant drink effect (P <.001) and drink time interaction (P<.001) were found for insulin concentrations. Insulin iaucs were significantly different between the drinks (P<.001). ISO, isomaltulose; ISO+WS, isomaltulose combined with whey/ soy (ratio 1:1); ISO+C, isomaltulose combined with casein; iauc, incremental area under the curve; ns, non-significant. Data are mean±sem. **P=.002, ***P<.001. iauc (pmol/l.4h) An overview of plasma amino acid concentrations at 0, 30 and 60 min is shown in Table 4. Total fasting plasma amino acid (TAA) concentrations did not differ on the study days when ISO + WS and ISO+ C were ingested (P =.651). TAA levels increased from baseline (P <.001) and were higher after administration of ISO + WS compared to those following administration of ISO+C (P<.001). Similarly, fasting plasma concentrations of essential amino acid (EAA) and branchedchain amino acid (BCAA) did not differ on the ISO+WS and ISO+C study days (P=.221 and P=.141, respectively). EAA and BCAA levels increased from baseline (P<.001) and showed a pattern similar to those of TAA. Moreover, both EAA and BCAA levels were higher after administration of ISO+WS than after administration of ISO+C (P<.001). Plasma TAA concentrations positively correlated with plasma insulin levels in the 60 min postprandial period following ingestion of ISO + WS and ISO+C (r s =.690 and r s =.684, P<.001, respectively). Plasma TAA, EAA, and BCAA responses were~54%, ~63%, and~59%, respectively, higher after administration of ISO+ WS than after administration of ISO+C (P<.001, Table 4). EAA and BCAA responses accounted for~52% 55% and~31% 32% of increases in TAA response after ingestion of both drinks, respectively. 4. Discussion The present study shows that ingestion of ISO+WS or ISO+C substantially increased insulin but did not reduce glucose

1700 METABOLISM CLINICAL AND EXPERIMENTAL 61 (2012) 1696 1702 Table 4 Plasma amino acid after ingestion of drinks containing ISO+WS and ISO+C in 30 type 2 diabetic patients. Amino acid ISO+WS (μmol/l) ISO+C (μmol/l) ISO+WS vs. ISO+C P value Baseline 30 min 60 min Baseline 30 min 60 min iauc (μmol/l.1 h) a,b Alanine 473±20 621±32 676±29 483±20 588±27 631±26 7501 ±781 5526±761 <.001 Arginine 79±3 116±5 108±5 76±3 96±5 86±4 1528 ±149 761±130 <.001 Asparagine 43±1 75±4 75±4 44±1 61±2 56±3 1430 ±133 698±90 <.001 Aspartic acid 10±1 13±1 12±1 10±1 11±1 10±1 142±23 55±9 <.001 Citrulline 35±2 34±2 35±2 33±2 34±2 34±3 32±10 68±16.035 Glutamine 457±23 500±24 509±23 463±21 495±24 483±25 2187 ±315 1451±250.047 Glutamic acid 160±19 178±16 175±17 157±14 171±16 171±16 1164±266 1004±210.798 Glycine 208±13 231±15 228±18 211±14 221±15 211±16 1030 ±221 423±105 <.001 Histidine 77±2 87±2 91±2 77±2 88±2 88±2 543±47 491±59.281 Isoleucine 88±4 166±7 168±7 86±4 131±6 114±5 3521 ±263 1795±219 <.001 Leucine 157±6 274±12 266±9 151±6 231±10 195±7 5127 ±424 3048±400 <.001 Lysine 177±7 270±10 264±9 173±5 235±9 212±6 4112±291 2456±333 <.01 Methionine 27±2 38±2 36±2 26±1 40±2 35±1 455±38 567±81.097 Phenylalanine 64±3 84±4 81±4 64±3 81±4 73±4 846±73 654±104.007 Serine 108±4 151±6 147±6 108±4 140±6 129±5 1880 ±194 1280±156 <.001 Taurine 106±9 115±11 113±11 112±9 124±11 119±10 690±230 744±192.827 Threonine 126±5 187±8 195±8 125±5 158±6 152±5 2846 ±239 1422±165 <.001 Tryptophan 59±2 76±2 80±3 60±2 68±2 64±2 808±72 354±59 <.001 Tyrosine 74±4 99±5 99±5 71±3 100±5 90±5 1123 ±121 1135±193.468 Valine 280±10 372±11 374±10 265±9 343±12 321±9 4154 ±343 3198±377.002 TAA 2811 ±43 3687 ±99 3733 ±91 2793 ±33 3416 ±85 3274 ±76 40115 ±3434 26055±3326 <.001 EAA 980±29 1467 ±43 1464 ±37 949±25 1288 ±41 1165 ±28 21878 ±1640 13454±1697 <.001 BCAA 526±20 813±28 807±25 501±18 704±27 630±20 12803 ±1004 8042±993 <.001 ISO+WS, isomaltulose combined with whey/soy (ratio 1:1); ISO+C, isomaltulose combined with casein; iauc, incremental area under the curve; TAA, total amino acid; EAA, essential amino acid; BCAA, branched-chain amino acid. Data are mean±sem. a For each individual amino acid, a P value<.0025 was considered significant (Bonferroni adjustment for 20 comparisons). b For TAA, EAA, and BCAA, a P value<.0167 was considered significant (Bonferroni adjustment for 3 comparisons). response compared to the ingestion of ISO alone in T2D subjects. Based on our results the explanation for this observation is a reduced postprandial insulin action after ingestion of ISO+WS or ISO+C. In healthy subjects, shortterm elevations of plasma amino acids have been shown to decrease glucose uptake, inhibit glucose transport or muscle insulin signaling, and enhance endogenous glucose production [24,25]. Taken together it can be concluded that protein components of ISO+WS and ISO+C decreased the effects of insulin in T2D subjects. Reduced insulin action is counterbalanced by an increase in insulin secretion, thereby regulating plasma glucose levels. Differences in insulin responses following ingestion of ISO+WS or ISO+C were exclusively dependent on the protein compositions as displayed by their amino acid profiles (P<.001). Our results confirm a previous report on the stimulation of insulin by postprandial TAA levels [26]. Differences in the rise of plasma TAA concentrations are attributed to a faster absorption of whey compared to casein. While whey proteins are readily soluble in gastric juice, caseins tend to clot in the stomach due to precipitation by gastric acid [27]. Overall, postprandial individual amino acid responses were enhanced after ingestion of ISO+WS as opposed to ingestion of ISO+C. Our results confirm previous findings of marked increments of alanine, leucine, valine, lysine, isoleucine, and threonine following the meals containing whey in healthy subjects [28,29]. The highest increase was seen in the alanine response, despite the fact that glutamic acid is the most abundant. This could be explained by transamination of glutamic acid to alanine during intestinal absorption [30], or increased conversion of glutamine to alanine due to substantial alterations of glutamine and alanine metabolism in type 2 diabetes [31]. The effects of ingestion of variable protein and carbohydrate combinations on glucose levels are discussed controversially. Non-diabetic probands often showed small, but significant absolute effects of total mean blood glucose when two carbohydrate/protein blends were compared [17,18], yet the shape of the glucose profiles did not differ [16]. In T2D subjects, the glucose responses were highly variable and the magnitude of glucose reduction was moderate at best [14,17,18]. Combining carbohydrate with casein reduced glucose responses, but glucose appearance rates [17] and plasma glucose levels [18] were identical compared to carbohydrate ingestion only. A reduced glucose response was further reported after whey intake for lunch, compared to a ham meal [32] without significant differences for breakfast with the same meals. Thus, no definitive conclusion on the glucose-lowering effect of protein can be drawn from these studies. Our study focused on the impact of protein ingestion on glucose and insulin responses, since study drinks contained only the macronutrients, carbohydrate and protein. By contrast, matrix and nutrient nutrient interactions will interfere with the contribution of the components in meal studies. Impaired insulin action is a major feature of type 2 diabetes and was calculated using the oral minimal model in our study. This model provides an accurate measurement of insulin sensitivity after ingestion of a single protein load and

1701 is as powerful as that obtained from an intravenous glucose tolerance test [23]. Insulin action was lower for ISO+WS compared to ISO+C drink, indicating that the type of ingested protein modulated insulin action. The fast-absorbing protein mixture whey/soy reduced insulin action to a greater extent than slow-absorbing casein. Interestingly, consumption of protein from animal sources (meat, milk/products, and cheese), but not from vegetables, was associated with a higher prevalence of diabetes [33]. Diets rich in protein may have long-term adverse effects on glycemic control, such as impaired suppression of hepatic glucose output by insulin, promotion of insulin resistance, and increased gluconeogenesis [34,35]. Dietary protein intake in diabetic patients usually ranges between 15% and 20% of total daily energy in most industrialized countries, which corresponds to 1.3 2.0 g/kg body weight and represents an intake that exceeds the recommended daily amount of 0.8 g/kg body weight. Recent epidemiological studies strongly indicate an association of higher intake of various proteins and increased risk of type 2 diabetes [33,36]. There are currently no guidelines addressing protein quality for the management of diabetes [37]. Our findings suggest that ingestion of fast-absorbing protein mixtures cannot be recommended for the glycemic control of T2D patients. Long-term effects of the consumption of proteins with different absorption rates remain to be established. In this study slowly absorbed ISO or the addition of ISO to both proteins increased glucose and insulin levels moderately. Incremental peak glucose and insulin levels were higher in previous studies with diabetic patients [14 18], but were similar after a lunch meal containing mashed potatoes and whey [32] compared to our study (~ 5 10 vs. ~ 3.5 mmol/l and ~ 500 1700 vs. ~ 120 380 pmol/l). Since the amounts of ingested carbohydrate (~ 45 60 g) and protein (~ 25 30 g) were comparable [14,15,18,32], part of the variation in publications may be explained by the differing carbohydrate sources (glucose, maltodextrin, or mashed potatoes). Altogether, modulating the type of carbohydrates in the diabetic diet was effective in controlling postprandial hyperglycemia. Results of metaanalyses support the use of low glycemic index foods in the metabolic control of diabetic patients [8,9]. In summary, a single drink containing ISO combined with whey/soy or casein elevated insulin levels, but reduced insulin action, and therefore did not improve glucose responses compared to the single drink of ISO alone. The whey/ soy drink increased insulin, which was associated with enhanced plasma amino acid levels, but concomitantly decreased insulin action compared to the casein drink. Thus, different types of proteins modulate insulin response and insulin action differently. A fast-absorbing protein reduces insulin action to a greater extent than a slow-absorbing protein. Our results suggest the importance of monitoring protein intake, as well as the type of protein, for the glycemic control of T2D patients. Author contributions MA carried out the data analysis and drafted the manuscript. ASM, FW, and AP contributed with valuable and critical discussion. TL coordinated the study and drafted the manuscript. Funding TL is supported by grants from Nutricia Advanced Medical Nutrition (Wageningen, Netherlands) and the Dutch Ministry of Agriculture and Food Quality. TL, FW, and AP are supported by the LOEWE focus group MIBIE, an excellence initiative of the state government of Hessen (Germany). Acknowledgments We thank the staff of the Clinical Research Unit for their technical assistance and the patients for their contribution to this study. We also thank Mirian Lansink and colleagues for contributing with the amino acid data and providing useful comments during the early development of the manuscript. Conflict of interest None of the authors has personal or financial conflicts of interest. REFERENCES [1] DECODE Study Group, the European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001;161:397 405. [2] Milicevic Z, Raz I, Beattie SD, et al. Natural history of cardiovascular disease in patients with diabetes: role of hyperglycemia. Diabetes Care 2008;31(Suppl. 2):S155 60. [3] Del Prato S. In search of normoglycaemia in diabetes: controlling postprandial glucose. Int J Obes Relat Metab Disord 2002;26(Suppl. 3):S9 17. [4] Ceriello A, Colagiuri S. International Diabetes Federation guideline for management of postmeal glucose: a review of recommendations. Diabet Med 2008;25:1151 6. [5] Psaltopoulou T, Ilias I, Alevizaki M. The role of diet and lifestyle in primary, secondary, and tertiary diabetes prevention: a review of meta-analyses. Rev Diabet Stud 2010;7:26 35. [6] Thomas GN, Jiang CQ, Taheri S, et al. A systematic review of lifestyle modification and glucose intolerance in the prevention of type 2 diabetes. Curr Diabetes Rev 2010;6:378 87. [7] Walker KZ, O'Dea K, Gomez M, et al. Diet and exercise in the prevention of diabetes. J Hum Nutr Diet 2010;23: 344 52. [8] Brand-Miller J, Hayne S, Petocz P, et al. Low-glycemic index diets in the management of diabetes: a meta-analysis of randomized controlled trials. Diabetes Care 2003;26: 2261 7. [9] Thomas DE, Elliott EJ. The use of low-glycaemic index diets in diabetes control. Br J Nutr 2010;104:797 802. [10] Jenkins DJ, Wolever TM, Taylor RH, et al. Glycemic index of foods: a physiological basis for carbohydrate exchange. Am J Clin Nutr 1981;34:362 6. [11] Lina BA, Jonker D, Kozianowski G. Isomaltulose (Palatinose): a review of biological and toxicological studies. Food Chem Toxicol 2002;40:1375 81.

1702 METABOLISM CLINICAL AND EXPERIMENTAL 61 (2012) 1696 1702 [12] Kawai K, Yoshikawa H, Murayama Y, et al. Usefulness of palatinose as a caloric sweetener for diabetic patients. Horm Metab Res 1989;21:338 40. [13] Holub I, Gostner A, Theis S, et al. Novel findings on the metabolic effects of the low glycaemic carbohydrate isomaltulose (Palatinose). Br J Nutr 2010;103:1730 7. [14] Gannon MC, Nuttall FQ, Neil BJ, et al. The insulin and glucose responses to meals of glucose plus various proteins in type II diabetic subjects. Metabolism 1988;37:1081 8. [15] Gannon MC, Nuttall FQ, Lane JT, et al. Metabolic response to cottage cheese or egg white protein, with or without glucose, in type II diabetic subjects. Metabolism 1992;41: 1137 45. [16] van Loon LJ, Kruijshoop M, Menheere PP, et al. Amino acid ingestion strongly enhances insulin secretion in patients with long-term type 2 diabetes. Diabetes Care 2003;26: 625 30. [17] Manders RJ, Wagenmakers AJ, Koopman R, et al. Co-ingestion of a protein hydrolysate and amino acid mixture with carbohydrate improves plasma glucose disposal in patients with type 2 diabetes. Am J Clin Nutr 2005;82:76 83. [18] Manders RJ, Koopman R, Sluijsmans WE, et al. Co-ingestion of a protein hydrolysate with or without additional leucine effectively reduces postprandial blood glucose excursions in Type 2 diabetic men. J Nutr 2006;136:1294 9. [19] Hageman R, Severijnen C, van de Heijning BJ, et al. A specific blend of intact protein rich in aspartate has strong postprandial glucose attenuating properties in rats. J Nutr 2008;138:1634 40. [20] Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412 9. [21] Trujillo-Arriaga HM, Román-Ramos R. Fitting and evaluating the glucose curve during a quasi continuous sampled oral glucose tolerance test. Comput Biol Med 2008;38: 185 95. [22] Caumo A, Bergman RN, Cobelli C. Insulin sensitivity from meal tolerance tests in normal subjects: a minimal model index. J Clin Endocrinol Metab 2000;85:4396 402. [23] Cobelli C, Toffolo GM, Dalla Man C, et al. Assessment of betacell function in humans, simultaneously with insulin sensitivity and hepatic extraction, from intravenous and oral glucose tests. Am J Physiol Endocrinol Metab 2007;293: E1 15. [24] Krebs M, Krssak M, Bernroider E, et al. Mechanism of amino acid-induced skeletal muscle insulin resistance in humans. Diabetes 2002;51:599 605. [25] Krebs M, Brehm A, Krssak M, et al. Direct and indirect effects of amino acids on hepatic glucose metabolism in humans. Diabetologia 2003;46:917 25. [26] Calbet JA, MacLean DA. Plasma glucagon and insulin responses depend on the rate of appearance of amino acids after ingestion of different protein solutions in humans. J Nutr 2002;132:2174 82. [27] Boirie Y, Dangin M, Gachon P, et al. Slow and fast dietary proteins differently modulate postprandial protein accretion. Proc Natl Acad Sci U S A 1997;94:14930 5. [28] Nilsson M, Stenberg M, Frid AH, et al. Glycemia and insulinemia in healthy subjects after lactose-equivalent meals of milk and other food proteins: the role of plasma amino acids and incretins. Am J Clin Nutr 2004;80: 1246 53. [29] Veldhorst MA, Nieuwenhuizen AG, Hochstenbach-Waelen A, et al. Dose-dependent satiating effect of whey relative to casein or soy. Physiol Behav 2009;96:675 82. [30] Joint FAO/WHO Expert Committee on Food Additives (JECFA). Toxicological evaluation of certain food additives. WHO Food Additives Series, No. 22. Geneva: Cambridge University Press; 1988. [31] Stumvoll M, Perriello G, Nurjhan N, et al. Glutamine and alanine metabolism in NIDDM. Diabetes 1996;45: 863 8. [32] Frid AH, Nilsson M, Holst JJ, et al. Effect of whey on blood glucose and insulin responses to composite breakfast and lunch meals in type 2 diabetic subjects. Am J Clin Nutr 2005;82:69 75. [33] Sluijs I, Beulens JW, van der ADL, et al. Dietary intake of total, animal, and vegetable protein and risk of type 2 diabetes in the European Prospective Investigation into Cancer and Nutrition (EPIC)-NL Study. Diabetes Care 2010;33:43 8. [34] Linn T, Geyer R, Prassek S, et al. Effect of dietary protein intake on insulin secretion and glucose metabolism in insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1996;81:3938 43. [35] Linn T, Santosa B, Grönemeyer D, et al. Effect of long-term dietary protein intake on glucose metabolism in humans. Diabetologia 2000;43:1257 65. [36] Liese AD, Weis KE, Schulz M, et al. Food intake patterns associated with incident type 2 diabetes: the Insulin Resistance Atherosclerosis Study. Diabetes Care 2009;32: 263 8. [37] Mann JI, De Leeuw I, Hermansen K, et al. Evidence-based nutritional approaches to the treatment and prevention of diabetes mellitus. Nutr Metab Cardiovasc Dis 2004;14: 373 94.